Nisa Investment Advisors
RLMD icon

Nisa Investment Advisors’s Relmada Therapeutics RLMD Stock Holding History

Nisa Investment Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400
Closed -$1K – 2675
2022
Q4 		$1K Buy
+400
New +$3.51K ﹤0.01% 2495
2022
Q3 		– Sell
-214
Closed -$4K – 2631
2022
Q2 		$4K Hold
214
– – ﹤0.01% 2300
2022
Q1 		$6K Sell
214
-4,863
-96% -$101K ﹤0.01% 2295
2021
Q4 		$93K Buy
5,077
+651
+15% +$14.5K ﹤0.01% 1540
2021
Q3 		$116 Sell
4,426
-458
-9% -$12.3K ﹤0.01% 1632
2021
Q2 		$156 Hold
4,884
– – ﹤0.01% 1499
2021
Q1 		$172 Hold
4,884
– – ﹤0.01% 1537
2020
Q4 		$157K Buy
+4,884
New +$168K ﹤0.01% 1571

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's RLMD Position: Q1 2023 in Review

Nisa Investment Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 400 shares — an estimated $1K sold.

Nisa Investment Advisors first reported a position in RLMD in Q4 2020 and held it in 8 quarters. The position peaked at $157K in Q4 2020. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Nisa Investment Advisors reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 400 Relmada Therapeutics shares in Q1 2023, an estimated $1K.
  • Nisa Investment Advisors first reported a position in Relmada Therapeutics in Q4 2020 and held it in 8 quarters.
  • Nisa Investment Advisors's Relmada Therapeutics position peaked at $157K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Nisa Investment Advisors's 13F filing for Q1 2023, filed 2 May 2023.